INC Research, a therapeutically focused CRO, and Debiopharm Group, a Swiss-based global biopharmaceutical group, have formed a strategic partnership.

INC will manage a clinical study linked to an important project in Debiopharm’s pipeline. Both parties have agreed on a framework partnership pertaining to future clinical studies to be conducted by INC for Debiopharm.

“Debiopharm’s reputation and success in establishing partnerships is aligned very closely with our vision of creating strategic relationships that improve the speed, efficiency, and quality of drug development,” said Kelvin Logan, Ph.D., president, INC Research Europe and Asia Pacific.

“This partnership with INC Research will significantly help us in our endeavors to conduct our clinical development programs efficiently, which in turn will enable us to continue to fuel our pipeline with important new medicines,” said Dr. Rolland-Yves Mauvernay, president and founder of Debiopharm.